Staun-Ram Elsebeth, Miller Ariel
Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel; Neuroimmunology Unit & Multiple Sclerosis Center, Carmel Medical Center, Haifa, Israel.
Clin Immunol. 2017 Nov;184:11-25. doi: 10.1016/j.clim.2017.04.014. Epub 2017 Apr 28.
The role of B cells in the pathogenesis of Multiple Sclerosis (MS), an autoimmune neurodegenerative disease, is becoming eminent in recent years, but the specific contribution of the distinct B cell subsets remains to be elucidated. Several B cell subsets have shown regulatory, anti-inflammatory capacities in response to stimuli in vitro, as well as in the animal model of MS: Experimental Autoimmune Encephalomyelitis (EAE). However, the functional role of the B regulatory cells (Bregs) in vivo and specifically in the human disease is yet to be clarified. In the present review, we have summarized the updated information on the roles of effector and regulatory B cells in MS and the immune-modulatory effects of MS therapeutic agents on their phenotype and function.
B细胞在多发性硬化症（MS）这一自身免疫性神经退行性疾病的发病机制中的作用近年来日益显著，但不同B细胞亚群的具体贡献仍有待阐明。几个B细胞亚群在体外受到刺激时以及在MS的动物模型——实验性自身免疫性脑脊髓炎（EAE）中均表现出调节、抗炎能力。然而，B调节细胞（Bregs）在体内尤其是在人类疾病中的功能作用仍有待明确。在本综述中，我们总结了效应B细胞和调节性B细胞在MS中的作用以及MS治疗药物对其表型和功能的免疫调节作用的最新信息。
